irofulven

04/01/2007 - "Preclinical studies and clinical trials have demonstrated that irofulven is effective against several tumor cell types. "
12/01/2006 - "Preclinical studies and clinical trials have shown that irofulven is effective against several tumor cell types. "
09/17/2004 - "Preclinical studies and clinical trials have demonstrated that irofulven is effective against several tumor types. "
05/01/2005 - "Irofulven, a novel chemotherapeutic agent with a broad spectrum of activity, is effective against preclinical models of pediatric tumors. "
03/01/2000 - "This study is part of an effort to evaluate efficacy of the novel agent MGI 114 (HMAF) against tumors resistant to conventional chemotherapeutic agents. "

03/01/2000 - "We evaluated the efficacy of MGI 114 against a human MRP+ lung carcinoma xenograft. "
03/01/2000 - "Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft."
05/01/1998 - "Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft."
10/01/2008 - "The human lung carcinoma MV522 cell line and its corresponding xenograft model were used to evaluate the activity of irofulven in combination with these different agents. "
07/01/2003 - "The cytotoxic activity of irofulven was particularly pronounced toward head and neck, non-small cell lung, colon, and ovary carcinoma cells, as well as toward malignant glioma cell lines. "

01/01/2001 - "Clinical trials with irofulven have shown significant activity and phase II studies in pancreatic, ovarian and prostatic cancer are ongoing. "
01/01/2001 - "These results suggest that PSA should be a reasonable marker of tumor burden in irofulven-treated prostate cancer patients."
02/01/2005 - "Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial."
11/01/2004 - "Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells."
01/01/2001 - "Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven."

04/01/2006 - "A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer."
02/15/2007 - "Furthermore, by using ovarian cancer cell lines expressing dominant-negative CHK2 and CHK2-knockout HCT116 cells, we found that CHK2 activation contributes to the control of S and G2/M cell cycle arrests, but not chemosensitivity to irofulven. "
09/01/2004 - "The potent activity of irofulven against ovarian tumors in vitro and in vivo supports the evaluation of its clinical activity in ovarian cancer."
09/01/2004 - "Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts."
09/17/2004 - "Phosphorylation of ATM on Ser(1981), which is critical for kinase activation, was observed in ovarian cancer cell lines treated with irofulven. "

01/01/2000 - "Due to the marked preclinical efficacy of MGI 114 against a variety of solid tumor xenografts, the current phase II human trials are restricted to solid tumor (breast, lung, colon, ovarian, pancreas, prostate, etc) malignancies. "
04/01/2006 - "Irofulven displays synergistic antiproliferative and pro-apoptotic effects when combined with oxaliplatin over a broad range of concentrations in human colon and breast cancer cells. "
01/01/2002 - "Irofulven induces significant, concentration and time-dependent apoptotic DNA fragmentation in breast cancer cell lines, regardless of caspase-3 status. "
01/01/2002 - "Irofulven action was compared in breast cancer cells differing in caspase-3 status: deficient MCF-7 cells and proficient MDA-MB-231 cells and in normal human mammary epithelial cells, HMEC. "
01/01/2002 - "Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status."